Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 1;35(2):120-127.
doi: 10.1097/QCO.0000000000000822.

Antibiotic treatment of acute bacterial skin and skin structure infections

Alessandro Russo  1 , Antonio Vena  2   3 , Matteo Bassetti  2   3
Affiliations
Review

Antibiotic treatment of acute bacterial skin and skin structure infections

Alessandro Russo et al. Curr Opin Infect Dis. .

Abstract

Purpose of review: Acute bacterial skin and skin structure infections (ABSSSI) are a leading cause of morbidity, with a considerable variety of clinical presentation and a wide range of etiological pathogens. Of importance, the spread of multidrug-resistant (MDR) strains (i.e. methicillin-resistant Staphylococcus aureus or Gram-negative bacteria) is increasingly reported in some regions. in this review, we summarize the current clinical approach to patients with ABSSSI.

Recent findings: Accurate diagnosis and identification of risk factors for MDR pathogens are key determinants for administering appropriate therapy in patients with ABSSSI. In daily clinical practice, this can be critical as there are many features defining the 'high risk patient' including both disease and host-associated risk factors.

Summary: Antibiotic therapy should be based according to the different clinical spectrum of disease belonging to the ABSSSI, on the pathogens most likely to be involved and local resistance. Careful evaluation of antibiotic therapy after 48-72 h of initial therapy could help clinicians to early identify patients with treatment failure and to consider an alternative approach. Close monitoring of patients with multiple comorbidities, drug-drug interaction or adverse host factors are also necessary.

PubMed Disclaimer

References

    1. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis 2009; 15:1516–1518.
    1. Garau J, Ostermann H, Medina J, et al. REACH study group. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect 2013; 19:E377–E385.
    1. Ray GT, Suaya JA, Baxter R. Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study. BMC Infect Dis 2013; 13:252.
    1. Jääskeläinen IH, Hagberg L, From J, et al. Treatment of complicated skin and skin structure infections in areas with low incidence of antibiotic resistance-a retrospective population based study from Finland and Sweden. Clin Microbiol Infect 2016; 22:383.e1–383.e10.
    1. Food and Drug Administration. Guidance for industry: acute bacterial skin and skin structure infections developing drugs for treatment. Available at: www.fda.gov/downloads/Drugs/./Guidances/ucm071185.pdf 2013. (Accessed 24 August 2016)

MeSH terms

Substances